W. J. Chng, A. Dispenzieri, C. S. Chim, R. Fonseca, H. Goldschmidt et al., IMWG consensus on risk stratification in multiple myeloma, Leukemia, vol.28, issue.2, pp.269-277, 2013.

S. Robiou-du-pont, A. Cleynen, C. Fontan, M. Attal, N. Munshi et al., Genomics of Multiple Myeloma, Journal of Clinical Oncology, vol.35, issue.9, pp.963-967, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01813387

J. Corre and H. Avet-loiseau, Risk-Based Therapeutic Strategies, The Cancer Journal, vol.25, issue.1, pp.54-58, 2019.

A. Palumbo, H. Avet-loiseau, S. Oliva, H. M. Lokhorst, H. Goldschmidt et al., Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, Journal of Clinical Oncology, vol.33, issue.26, pp.2863-2869, 2015.

S. Lonial, M. Dimopoulos, A. Palumbo, D. White, S. Grosicki et al., Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, New England Journal of Medicine, vol.373, issue.7, pp.621-631, 2015.

H. Avet-loiseau, M. Attal, and P. Moreau, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, vol.109, issue.8, pp.3489-3495, 2007.

A. Thakurta, M. Ortiz, P. Blecua, F. Towfic, J. Corre et al., High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma, Blood, vol.133, issue.11, pp.1217-1221, 2019.

J. Drach, J. Ackermann, E. Fritz, E. Kro?mer, R. Schuster et al., Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy, Blood, vol.92, issue.3, pp.802-809, 1998.

E. Flynt, K. Bisht, V. Sridharan, M. Ortiz, F. Towfic et al., Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma, Cells, vol.9, issue.2, p.287, 2020.

B. A. Walker, K. Mavrommatis, C. P. Wardell, T. C. Ashby, M. Bauer et al., A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis, Leukemia, vol.33, issue.1, pp.159-170, 2018.

S. V. Rajkumar, J. L. Harousseau, B. Durie, K. C. Anderson, M. Dimopoulos et al., Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, vol.117, issue.18, pp.4691-4695, 2011.

L. Lode, M. Eveillard, V. Trichet, T. Soussi, S. Wuilleme et al., Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, issue.11, pp.1973-1976, 2010.

S. Thanendrarajan, E. Tian, P. Qu, P. Mathur, C. Schinke et al., The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma, Haematologica, vol.102, issue.9, pp.e364-e367, 2017.